ATE414088T1 - Polymorphe formen eines gabaa-agonisten - Google Patents

Polymorphe formen eines gabaa-agonisten

Info

Publication number
ATE414088T1
ATE414088T1 AT05702040T AT05702040T ATE414088T1 AT E414088 T1 ATE414088 T1 AT E414088T1 AT 05702040 T AT05702040 T AT 05702040T AT 05702040 T AT05702040 T AT 05702040T AT E414088 T1 ATE414088 T1 AT E414088T1
Authority
AT
Austria
Prior art keywords
polymorphoic
forms
gabaa agonist
gabaa
agonist
Prior art date
Application number
AT05702040T
Other languages
German (de)
English (en)
Inventor
Vincent Brett Cooper
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE414088(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE414088T1 publication Critical patent/ATE414088T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05702040T 2004-01-30 2005-01-28 Polymorphe formen eines gabaa-agonisten ATE414088T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist

Publications (1)

Publication Number Publication Date
ATE414088T1 true ATE414088T1 (de) 2008-11-15

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05702040T ATE414088T1 (de) 2004-01-30 2005-01-28 Polymorphe formen eines gabaa-agonisten

Country Status (34)

Country Link
US (2) US7262300B2 (https=)
EP (2) EP1713813B1 (https=)
JP (1) JP4917440B2 (https=)
KR (1) KR101210361B1 (https=)
CN (1) CN1914212B (https=)
AR (1) AR047511A1 (https=)
AT (1) ATE414088T1 (https=)
AU (1) AU2005209473B2 (https=)
BR (1) BRPI0506858A (https=)
CA (1) CA2554536C (https=)
CO (1) CO5700743A2 (https=)
CY (1) CY1108647T1 (https=)
DE (1) DE602005010975D1 (https=)
DK (1) DK1713813T3 (https=)
DO (1) DOP2005000013A (https=)
EA (1) EA009413B1 (https=)
EC (1) ECSP066735A (https=)
ES (1) ES2314613T3 (https=)
GB (2) GB0402118D0 (https=)
HR (1) HRP20080614T3 (https=)
IL (1) IL176863A0 (https=)
MA (1) MA28364A1 (https=)
MX (1) MXPA06008595A (https=)
MY (1) MY139525A (https=)
NO (1) NO20063843L (https=)
NZ (1) NZ548191A (https=)
PE (1) PE20050769A1 (https=)
PL (1) PL1713813T3 (https=)
PT (1) PT1713813E (https=)
SI (1) SI1713813T1 (https=)
TW (1) TWI345972B (https=)
UA (1) UA87487C2 (https=)
WO (1) WO2005073237A2 (https=)
ZA (1) ZA200605307B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
WO2006083682A2 (en) * 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
ES2524994T3 (es) 2005-09-28 2014-12-16 Auris Medical Ag Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
EP2790686B1 (en) 2011-12-12 2021-03-10 Zilentin Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
EP3528807A4 (en) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
EP3880201A4 (en) 2018-12-17 2022-07-27 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF NON-24 HOUR SLEEP waking disorder
EP4051272A4 (en) 2019-12-18 2023-01-04 Ovid Therapeutics Inc. GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1P36 DELETION SYNDROME
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4315934A (en) 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
EP1220658A1 (en) 1999-09-28 2002-07-10 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
CA2447417C (en) 2001-05-18 2011-10-04 Lonza Ag Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate
CN1511026A (zh) 2001-05-21 2004-07-07 H��¡�±������޹�˾ 加波沙朵颗粒制剂
CN100491366C (zh) * 2002-09-03 2009-05-27 华晶基因技术有限公司 汉黄芩素用作治疗焦虑症的药物的用途
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
DK1641456T3 (da) * 2003-06-25 2010-06-21 Lundbeck & Co As H Gaboxadol til behandling af depression og andre affektive lidelser
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2008504306A (ja) 2004-06-29 2008-02-14 ハー・ルンドベック・アクチエゼルスカベット 神経因性疼痛、線維筋痛症または慢性関節リウマチの治療
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
WO2006083682A2 (en) 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
WO2006102093A1 (en) 2005-03-18 2006-09-28 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol

Also Published As

Publication number Publication date
CO5700743A2 (es) 2006-11-30
HK1096547A1 (en) 2007-06-01
CA2554536A1 (en) 2005-08-11
AR047511A1 (es) 2006-01-25
EP2042505A1 (en) 2009-04-01
BRPI0506858A (pt) 2007-05-29
NZ548191A (en) 2010-04-30
WO2005073237A2 (en) 2005-08-11
US8236958B2 (en) 2012-08-07
PE20050769A1 (es) 2005-10-04
ECSP066735A (es) 2006-10-31
EP1713813B1 (en) 2008-11-12
TWI345972B (en) 2011-08-01
US20070259912A1 (en) 2007-11-08
DK1713813T3 (da) 2009-02-16
DOP2005000013A (es) 2005-08-15
WO2005073237A3 (en) 2005-10-20
EP1713813A2 (en) 2006-10-25
KR101210361B1 (ko) 2012-12-10
ES2314613T3 (es) 2009-03-16
GB2410434A (en) 2005-08-03
MY139525A (en) 2009-10-30
CN1914212A (zh) 2007-02-14
TW200534856A (en) 2005-11-01
GB0501847D0 (en) 2005-03-09
NO20063843L (no) 2006-08-29
EA200601404A1 (ru) 2006-12-29
PT1713813E (pt) 2008-12-26
AU2005209473A1 (en) 2005-08-11
ZA200605307B (en) 2007-11-28
JP4917440B2 (ja) 2012-04-18
SI1713813T1 (sl) 2009-02-28
CN1914212B (zh) 2010-10-06
US20050171142A1 (en) 2005-08-04
PL1713813T3 (pl) 2009-04-30
CY1108647T1 (el) 2014-04-09
HRP20080614T3 (en) 2009-01-31
KR20070007070A (ko) 2007-01-12
MXPA06008595A (es) 2006-08-28
MA28364A1 (fr) 2006-12-01
CA2554536C (en) 2012-09-18
UA87487C2 (ru) 2009-07-27
EA009413B1 (ru) 2007-12-28
JP2007519697A (ja) 2007-07-19
DE602005010975D1 (de) 2008-12-24
IL176863A0 (en) 2006-10-31
AU2005209473B2 (en) 2010-03-04
US7262300B2 (en) 2007-08-28
GB0402118D0 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
ATE414088T1 (de) Polymorphe formen eines gabaa-agonisten
EP1890546A4 (en) COMPOSITION FOR INCREASING THE BIOLOGICAL AVAILABILITY OF CURCUMIN
DE112005001544T5 (de) Innen-einsetzbares Rohr-Untersuchungswerkzeug
DE602006007563D1 (de) Agonisten
DE602007003661D1 (de) Plattformflosse eines Gebläses
DE602007004016D1 (de) Fahrradkurbel
EP2089722A4 (en) BIOMARKERS
EP2049032A4 (en) IMPROVED IMPINGER
DE602006003003D1 (de) Abgassystem eines Motorrads
DE602007000459D1 (de) Fahrradtretkurbel
DE602006017539D1 (de) Buchsenprofilstruktur eines synchronisators
ATE509924T1 (de) Neue salzform eines dopaminagonisten
DK2062053T3 (da) Forbedret immunoanalysefremgangsmåde
DE602005017539D1 (de) Verifikation eines Bitstromes
EP1848420A4 (en) POLYMORPH SHAPES OF A GABAA AGONIST
FR2896995B1 (fr) Raquette de paddleball
DE602006014927D1 (de) Prüfvorrichtung
EP1962026A4 (en) INDOOR UNIT OF AN AIR-CONDITIONING SYSTEM
FI20050681A0 (fi) Paikoitusmenetelmä
DE602004016780D1 (de) Turbine eines turboladers
DE602006015610D1 (de) Pedalanordnung eines Übungsgerätes
DE602006008015D1 (de) Feste salzformen eines pyrrolsubstituierten 2-indolinons
EP1974292A4 (en) RESEARCH ENGINE COMPRISING A MECHANISM FOR CORRELATION OF INFORMATION
DE112006000188A5 (de) Zylinder-Kurbelgehäuse
DE602007001897D1 (de) Prüfvorrichtung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1713813

Country of ref document: EP